# INDEX

AAALAC, 39, 121  
Acetaminophen toxicity, 244  
ACVP, 25  
Ames test, 142  
Aroclor 1254, 143  
Association for Assessment and Accreditation of Laboratory Animal Care, 39  
Benchmark toxicology strategy, 113  
Biomarkers, 239  
Bridging toxicology studies, 112  
Carcinogenicity Assessment Committee (CAC), 127  
CCRIS, 223  
Chemical Safety Report, 5  
Chromosomal diseases, 3  
Chromosome breakage, 140  
Clastogenesis, 140  
Comet assay, 154  
Conflict resolution in study teams, 22  
Constitutive genes, 3  
Contract Research Organizations (CRO), 19  
Critical mass of a CRO, 36  
Evaluating study personnel at a CRO, 36  
Historical database of study parameters, 35  
Mistakes in CRO selection, 33  
Monitoring studies, 41  
Prequalification visit, 40  
Selection of a CRO, 32  
Study monitoring team, 41  
Study report preparation and review, 45  
Core battery of genetic toxicology tests, 141  
Core toxicology studies, 112  
Decision criteria for outsourcing studies, 20  
Developmental toxicity  
Choice of test species, 172  
Data interpretation, 190  
Dose level selection, 173  
Embryofetal development study, 176  
Guidelines, 168  
Integrated analysis, 193  
Malformations, 192  
Maternal toxicity, 190  
Pre-and postnatal study, 177  
Segment 2 study, 176  
Segment 3 study, 177  
Toxicokinetics, 173  
Variations, 192  
DNA adducts, 153  
DNA-reactive mechanisms of genotoxicity, 153  
Drug withdrawal  
Vioxx, 2  
ECVAM, 147  
EMEA, 110  
End of Phase 2 meeting, 235  
European Board of Pathology, 25  
European Registered Toxicologist, 23  
EUROTOX, 23  
Evaluation of clinical signs, 26  
Expeditied nonclinical development programs, 115  
Exploratory IND, 116  
FDA, 110  
FDA Redbook, 117  
Formulations  
Liquid formulations, 84  
Solid formulations, 86  
Concentration, 86  
Homogeneity, 86  
Stability of the test compound, 87  
Frameshift mutations, 140

*Pharmaceutical Toxicology in Practice: A Guide for Non-Clinical Development*, Edited by Alberto Lodola and Jeanne Stadler  
© 2011 John Wiley & Sons, Inc.
INDEX

General Toxicology
Animal care, 120
Blood sampling, 130
Choice of dose levels, 124
Choice of test species, 118
Choice of vehicle, 123
Compound administration, 121
Core toxicology studies, 116
Guidelines, 111
In-life observations, 128
Laboratory measurements, 131
Necropsy and histopathology, 133
Strategy development, 112
Study design, 116
Study Protocol, 119
Support of clinical studies, 113
Genetic polymorphism, 247
Genotoxicity screening, 150
GLP, 118

Harmonization of histopathology data, 25
Heinz bodies, 149
High-throughput bacterial mutation assay, 151
Housing and welfare of animals, 120
HSDB, 222

ICH guidelines
Overview, 15
NCE and NBE-guidelines, 16
Key players, 11
Process description, 12

Impurities
Clinical studies, 90
Degradation products, 89
Early development, 88
Full development, 90
Genotoxic impurities, 90
Metal residues, 94
Non clinical studies, 89
Reactive metabolites, 92
Solvent residues, 94
Synthesis intermediates, 89
in vitro chromosome aberration assay, 145
in vitro micronucleus assay, 146
in vitro mouse lymphoma assay, 143
In vitro toxicology, 118
in vivo rodent micronucleus assay, 147
Inducible genes, 3
Initiating a study at a CRO, 32
Insourcing versus outsourcing, 20
Investigative/Mechanistic toxicology studies, 112

Juvenile toxicity
Study objectives, 182
Selection of animals, 183
Dose level selection, 185
Constitution of study groups, 186
Dosing animals, 186
Formulations, 188
Study conduct, 188
Prewhealing evaluations, 189
Postweaning evaluations, 189
Key factors in the induction of toxicity, 109
Koseirodosho, 110

LD50, 110

MHLW, 110
Micronuclei, 146
Mitotic index, 149
MLA assay, 143
Monogenic diseases, 3
MTD, 110, 124, 148
Multifactorial diseases, 3
Multiple-site toxicity studies, 19

Narrow Therapeutic Index, 238
National Toxicology Program, 118
NOAEL, 22, 110, 124
NOEL, 110
Nonclinical data interpretation, 200
Nonclinical study data analysis, 200
Nonclinical risk management strategy development, 231
Nonregulatory studies, 118
NSAID, 2
NTI, 238
NTIS, 221
NTP, 221
NTP technical reports, 223
OEC study designs, 117
Omic technologies, 4
Organizational structures, 28
INDEX

Parameters monitored in toxicology studies, 117
Peer review of data, 209
Peer review of histopathology data, 134
Polyploid index, 149
pre-IND meeting, 235
Process-based inspections, 40
QT-interval and risk management, 240
REACH, 5
Recommended blood sampling volumes, 131
Recommended dosing volumes, 122
Registry of Industrial Toxicology Animal Data, 25
Regulatory studies, 118
Reproductive toxicity
  Choice of test species, 172
  Data interpretation, 190
  Dose level selection, 173
  Endocrine disruptors, 166
  Fertility study, 174
  Guidelines, 168
  Integrated analysis, 193
  Segment 1 study, 174
  Toxicokinetics, 173
Resource management, 28
Risk Management, 229
Risk management of Thalidomide, 245
Risk management using Safety Margins, 237
Risk Management process, 232
Risk perception, 230
RITA, 25
Roles and responsibilities
  Conflict resolution, 22
  Management, 26
  The Study Director, 23
  The Study Pathologist, 25
  The Study Team, 21
  The Technical staff, 26
S.T.E.P.S. program, 246
S9-mix, 143
Safety pharmacology
  Choice of dose levels, 56
  Choice of test species, 56
  Chronically instrumented animals, 73
  CNS evaluation, 69
  CNS findings - in vitro models, 73
  CNS findings - in vivo models, 73
  Core battery of tests, 58
  Drug abuse and dependence, 73
  Experimental models, 55
  GI function, 76
  Guidelines, 52
  hERG inhibition, 64
  In vitro Cardiovascular Study, 64
  In vitro Models for Cardiovascular Findings, 70
  In vivo Cardiovascular Study in Nonrodents, 58
  In vivo models for cardiovascular findings, 72
  In vivo models for respiratory findings, 72
  In vitro cardiovascular study - High-Throughput Systems, 67
  Patch-Clamp Protocol, 65
  Plethysmography, 67
  Purkinje fibers test, 70
  QT Correction and QT/RR Analysis, 61
  Renal function, 75
  Respiratory study in rodents, 67
  Route of administration, 57
  Telemetry using the anesthetised dog, 72
  The guinea pig papillary muscle test, 70
  The ventricular wedge preparation, 71
  Transmural ECG, 71
  Severity of clinical signs, 125
  SHE assay, 156
  Siderocytes, 149
  Single-site toxicity studies, 19
  Study Director selection for a CRO study, 36
  Study Director study assignment, 24
  Study Monitor selection for a CRO study, 37
  Study Protocol, 118
  Study reports
    Discussion section, 218
    Format, 211
    Results section, 214
    Summary section, 219
    Toxicology data bases, 220
  Study-base inspections, 40
Submission documents
  Pharm/tox review FDA, 221
  Syrian Hamster embryo cell transformation assay, 156
  Tamoxifen, 247
258

INDEX

TEHIP, 222
Thyroid hyperplasia, 243

Toxicokinetics
Absorption, 100
Carcinogenicity studies, 97
Developmental toxicity studies, 98
Distribution, 100
Gender differences, 102
General principles of analysis, 98
In-diet studies, 97
Interpretation of data, 99
Linear kinetics, 103
Liver elimination of drugs, 101
Non linear kinetics, 103
Range-finding studies, 95
Renal elimination of drugs, 101

Reproductive toxicology studies, 98
Sub-chronic studies, 97

Toxicology
Definition, 1
Milestones, 1
Subdisciplines, 1
Toxicology studies
Choice of test species, 118
TOXLINE, 222

Unscheduled DNA synthesis assay, 154
VIGOR study, 2
Warfarin, 247
Weight of evidence (WOE) and risk assessment, 152